{"name":"Attaya Suvannasankha","slug":"attaya-suvannasankha","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5hRWYyckpRNUV6dXJDOThUYy10N2Z6UFNRLVc5c2hjclhsYzFkZkZfdXc3eDJIWUJtR1hzUmtsQXR6a05xckVsRWpraFZweGo5NXhfMXcxSmIxcmstbGZSMnRrWDJGY0gyWkFMN0toaUpTT3g2QTRkSTBEWQ?oc=5","date":"2024-04-17","type":"pipeline","source":"acsjournals.onlinelibrary.wiley.com","summary":"Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma - acsjournals.onlinelibrary.wiley.com","headline":"Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNSGhRbzRwTHFIMldtZDZSaXV5c0JQVHpvZF81SjFWcVBlaERGbFVwTnd2RlhfTEQtYk1NSE1td0tieVJtUWM5VTh4N25vV3hqR3AxS2lJc1NONnlkSzM0TmVlYnNoS2x2cmUxT2E1blJNMTZxeDk1SkVVbDRSWTlLR1l1UklDYVJqSGJ4TmFxQTBBZkNjWVhMQzRhQVkxaVdWeFJjY1N3?oc=5","date":"2023-05-09","type":"pipeline","source":"OncLive","summary":"REGN5459 Demonstrates Early Promise in Heavily Pretreated Multiple Myeloma - OncLive","headline":"REGN5459 Demonstrates Early Promise in Heavily Pretreated Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQZUVDclBkSmF5QzY0T3RzZEtmbV9DX05rZTRVX3M2UG5heGtkcDVXbGN3bDl0Y05qWHh2d3IxWnRBbERNbHhZa09ZQ20wdHBKTGp2QXJFQTVTSmtVUk5UOFgzOVJaWDFuOEdibFNMMjRCTTJUaURObGZkNkxzMjBIMnczLVZVbnJ2YzFXZVg1YzVXZl9VZk5Lb3V3dENRWWpITlZnak1XRXE4dHNXZFNUSw?oc=5","date":"2023-04-18","type":"trial","source":"Oncology News Central","summary":"BCMA x CD3 Bispecific Shows Promise in R/R MM in Early Data - Oncology News Central","headline":"BCMA x CD3 Bispecific Shows Promise in R/R MM in Early Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNeGpQR2R1TDR3TVBaeWtMUVV6TUpMN210NzFvQlNZMTRiT3cyY21nclRYRzRmakROWVRvM1gwTklJaS00RVd2a3h6RG1sYTVCWjhzMW9XZksySmVyTFBSbVM5d0pZQTNidnctQjJ3S3JBUnZGRDRNVGs4MlptNWVROUhaM0I1OTE5VVk3ano2UVVjakxFWkx1a0h5X2JTejJpbXFrd1IzUnZ5OFZpYnV6cTdwRWNGVGZuZk1KbGxmRllmbGdIN1E0aXEyYkFhdXBsc3F0cENQTmQxUVBCcE53?oc=5","date":"2023-04-18","type":"pipeline","source":"Healio","summary":"Low-affinity bispecific antibody produces high response rates in advanced multiple myeloma - Healio","headline":"Low-affinity bispecific antibody produces high response rates in advanced multiple myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQS3NKYUJrMU13bU9VZlFkSTVlSkw0Z1NlMTRaeWlBeGJwU3pLbThZc2pvWS16NXg2OEF3OURqY2RncF9tOTBTeUtkSVdPeS1Rdk9VdVJKb1BJU1JaanRmMHhzczBqWlNUbmJNZXJROHJXcXd0VTRteHA3ekRZRmhndGlZUTN1T2pSX2pKbVJjdzJNWWg3M2UyZVNlalM0VmlCTFVkNg?oc=5","date":"2023-04-17","type":"pipeline","source":"OncLive","summary":"REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma - OncLive","headline":"REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQeHR0OFBiMl9zZ0dNNUhHQkFTblVZN29XYndpQjZVbEl2TmNDbUxENHNTM3dWVE41c0ZqNTdaR3NvR3BqS3JuTWlYSmVyaWdkSDVHR2dUNmFRbG9jTmtUX1NQMi1oTmN3SkRyT2xtZ2JkSkZfbjRnWlJnRE1lQ25nMktMNHJyUjRFSk5FRVcycG8ycG5GUndMZzlneVJOUVJ3QlZVUmZOOWdPYkVvZjJabGJ4OFpaSF9m?oc=5","date":"2023-04-17","type":"pipeline","source":"Cancer Health","summary":"New Bispecific Antibody Demonstrates Clinical Activity in Patients With Multiple Myeloma - Cancer Health","headline":"New Bispecific Antibody Demonstrates Clinical Activity in Patients With Multiple Myeloma","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}